Listen Get

Drug Development Cost Increase Analysis

Keywords

war-on-disease, 1-percent-treaty, medical-research, public-health, peace-dividend, decentralized-trials, dfda, dih, victory-bonds, health-economics, cost-benefit-analysis, clinical-trials, drug-development, regulatory-reform, military-spending, peace-economics, decentralized-governance, wishocracy, blockchain-governance, impact-investing

The Short Version

In 1960, developing a new drug cost $24.7 million (95% CI: $19.5 million-$30 million) in today’s dollars. Now it costs $2.6 billion (95% CI: $1.5 billion-$4 billion). That is 105x (90% CI: 72.8x-149x) more. Adjusted for inflation. Using real academic data (Baily 1972). The drugs are not 105x (90% CI: 72.8x-149x) better.

Four things drove this:

  1. Timelines exploded. 2-3 years became 10-15 years. The drug does not take longer to invent. The paperwork takes longer to complete.
  2. Failure rates climbed. More capital at risk per approved drug.
  3. Regulations multiplied. The 1962 Kefauver-Harris Amendment added layers of proof that a drug works, after you already proved it was safe. The layers have been adding layers ever since.
  4. Trial costs ballooned. Cost per patient increased by 82x (90% CI: 21.4x-195x). The patient is not 82x (90% CI: 21.4x-195x) sicker.

Below: the math, the sources, and six real-world sanity checks proving this isn’t an exaggeration.

Historical Data Sources

Pre-1962 Drug Development Costs

Primary Source: Baily (1972) Academic Study

The average cost per new chemical entity (NCE) in the pre-1962 era was $6.5 million (95% CI: $5.2 million-$7.8 million) (1980 dollars), which adjusts to $24.7 million (95% CI: $19.5 million-$30 million) (2024 dollars).

Source: Baily, Martin Neil (1972), “Research and Development Costs and Returns: The U.S. Pharmaceutical Industry,” cited in Health Affairs 1982, The Importance of Patent Term Restoration1

This covers the total cost to bring a drug from discovery through FDA approval under the pre-1962 regime (safety-only testing). It’s the best academic estimate available.

Before FDA regulation, drugs cost 12 to 25 million to develop. Experts disagree on the exact number. Both are smaller than what we write here in comas.

Before FDA regulation, drugs cost 12 to 25 million to develop. Experts disagree on the exact number. Both are smaller than what we write here in comas.

Alternative: Congressional Testimony (1977)

Congress cited $1.2 million (1962 dollars) = $12 million (2024 dollars). Lower than Baily, probably due to incomplete cost accounting. The Baily study is more thorough.

Current Drug Development Costs

Tufts CSDD (2014):

The average cost to develop and gain approval for a new drug is $2.6 billion (95% CI: $1.5 billion-$4 billion) (2013 dollars).

Source: Tufts Center for the Study of Drug Development, 2014

This includes:

  • Preclinical research
  • Clinical trials (Phases I-III)
  • Cost of failures (for every approved drug, ~9 fail)
  • Cost of capital (time value of money over 10-15 years)

FDA Data (2023):

FDA approved 50 drugs/year (95% CI: 45 drugs/year-60 drugs/year) new drugs per year (2018-2023 average), down from 60+ per year in the 1950s, despite vastly higher R&D spending.

Why drugs cost 2.6 billion dollars: most of them fail, and it takes forever. In the 1950s it was faster and cheaper. Progress: occasionally backwards.

Why drugs cost 2.6 billion dollars: most of them fail, and it takes forever. In the 1950s it was faster and cheaper. Progress: occasionally backwards.

Inflation-Adjusted Calculations

Primary Method: Baily (1972) Academic Study

Step 1: Adjust 1980 dollars to 2024 dollars

\[ \text{Pre-1962 cost in 2024 dollars} = \$6.5M \times \text{CPI multiplier}_{1980 \to 2024} \]

Using the Bureau of Labor Statistics CPI calculator2:

\[ \$6.5M \times 3.80 = \$24.7M \]

Therefore, the pre-1962 drug development cost in 2024 dollars is $24.7 million (95% CI: $19.5 million-$30 million).

Step 2: Calculate real cost increase

\[ \begin{gathered} k_{cost,pre62} \\ = \frac{Cost_{dev,curr}}{Cost_{pre62,24}} \\ = \frac{\$2.6B}{\$24.7M} \\ = 105 \end{gathered} \]

Alternative Method: Congressional Testimony (1977)

Step 1: Adjust 1962 dollars to 2024 dollars

  • $1.2M (1962 dollars)
  • CPI multiplier (1962 → 2024): 10.13×
  • $1.2M × 10.13 = $12.2M (2024 dollars)

Step 2: Calculate real cost increase

\[ \text{Cost multiplier} = \frac{\$2.6B}{\$12.2M} = 213\text{×} \]

Upper-bound estimate: 213x. The Baily study (105x (90% CI: 72.8x-149x)) is used here because it’s more rigorous.

Drugs used to cost 25 million to develop. Now they cost 2.6 billion. That’s 105 times more expensive. Inflation doesn’t explain this. Regulation does.

Drugs used to cost 25 million to develop. Now they cost 2.6 billion. That’s 105 times more expensive. Inflation doesn’t explain this. Regulation does.

Why Inflation Doesn’t Explain This

The 105x (90% CI: 72.8x-149x) increase comes from four things stacking on top of each other:

Development Timeline Expansion

Era Average Timeline Opportunity Cost
Pre-1962 2-3 years Minimal
Post-1962 10-15 years Massive (compounding at cost of capital)

Cost of capital impact: $100M invested for 12 years at pharma’s 10% hurdle rate:

\[ \text{Present value cost} = \$100M \times (1.10)^{12} = \$314M \]

A 12-year delay adds 3.14× to costs via time value of money alone.

Higher Failure Rates

For every drug that works, nine fail. That’s a 90 percent failure rate. Pharma: where F students become billionaires or bankrupt. No middle ground.

For every drug that works, nine fail. That’s a 90 percent failure rate. Pharma: where F students become billionaires or bankrupt. No middle ground.

The Tufts CSDD figure includes cost of failures:

  • For every drug that gets approved, 9 fail
  • Total capital at risk: 10x the nominal cost per success
  • Pre-1962 failure rates were lower. Simpler approval, shorter timelines, less money on fire.

Trial Complexity

Pre-1962 (RECOVERY trial equivalent):

  • Simple randomization
  • Hospital-integrated data collection
  • Minimal regulatory burden
  • Cost per patient: ~$50 (modern pragmatic trials median: $97 (95% CI: $19-$478)3)

Post-1962 (typical FDA Phase III):

  • Complex inclusion/exclusion criteria
  • Separate CRO infrastructure
  • Extensive monitoring and auditing
  • Cost per patient: ~$4,100

See Regulatory Mortality Analysis for full derivation.

Old trials: give people pills, see what happens. New trials: seventeen phases, forty committees, infinite paperwork. One costs 500 dollars. One costs 41,000 dollars. Guess which.

Old trials: give people pills, see what happens. New trials: seventeen phases, forty committees, infinite paperwork. One costs 500 dollars. One costs 41,000 dollars. Guess which.

Preclinical Requirements

Post-1962 regulations added years of preclinical work before you can touch a human:

  • Toxicology studies (multiple species)
  • Carcinogenicity studies (2-year rodent studies)
  • Reproductive toxicity studies
  • Pharmacokinetic studies
  • Good Laboratory Practice (GLP) compliance

These requirements added 2-3 years and $50-100M per drug candidate.

Five things you must do before human trials: toxicology, pharmacology, formulation, manufacturing, and regulations. Takes years. Costs millions. Prevents exactly zero deaths.

Five things you must do before human trials: toxicology, pharmacology, formulation, manufacturing, and regulations. Takes years. Costs millions. Prevents exactly zero deaths.

How Solid Is This Number?

The 105x (90% CI: 72.8x-149x) multiplier depends on three inputs:

  1. Pre-1962 cost ($6.5M in 1980 dollars, Baily 1972)
  2. CPI multiplier (1980 to 2024)
  3. Current cost ($2.6B in 2013 dollars, Tufts CSDD)

Which Inputs Matter Most

Full Range of Outcomes

Monte Carlo Distribution: Drug Cost Increase: Pre-1962 to Current (10,000 simulations)

Monte Carlo Distribution: Drug Cost Increase: Pre-1962 to Current (10,000 simulations)

Simulation Results Summary: Drug Cost Increase: Pre-1962 to Current

Statistic Value
Baseline (deterministic) 105x
Mean (expected value) 107x
Median (50th percentile) 104x
Standard Deviation 22.9x
90% Range (5th-95th percentile) [72.8x, 149x]

The histogram shows 1,000 of the 10,000 Monte Carlo draws for Drug Cost Increase: Pre-1962 to Current; the summary statistics use all 10,000. The exceedance curve (right) shows the probability of the outcome exceeding any given value.

10,000 Monte Carlo runs. Even when you vary every input at once, the cost multiplier stays large across all plausible scenarios.

Input Distributions

Probability Distribution: Pre-1962 Drug Development Cost (1980 Dollars)

Probability Distribution: Pre-1962 Drug Development Cost (1980 Dollars)

This chart shows the assumed probability distribution for this parameter. The shaded region represents the 95% confidence interval where we expect the true value to fall.

Probability Distribution: Pharma Drug Development Cost (Current System)

Probability Distribution: Pharma Drug Development Cost (Current System)

This chart shows the assumed probability distribution for this parameter. The shaded region represents the 95% confidence interval where we expect the true value to fall.

Alternative Scenarios

Scenario Pre-1962 Cost (2024$) Current Cost Multiplier
Primary Estimate (Baily 1972 study) $24.7 million (95% CI: $19.5 million-$30 million) (1980 baseline)

$2.6 billion (95% CI: $1.5 billion-$4 billion)

 105x (90% CI: 72.8x-149x)
Alternative (Upper Bound) (Congressional 1977) $12.2M (1962 baseline) $2.6B 213×
Speculative Maximum (early 1960s) $8.0M (1960 baseline) $2.6B 325×

Independent Validation

Other researchers found the same thing:

“The cost of drug development has increased by a factor of approximately 100 to 400 times from the 1960s to the 2010s, depending on baseline assumptions.”

Sources: Multiple studies (Baily 19721, DiMasi et al. 20164, Tufts CSDD 20145)

The 105x (90% CI: 72.8x-149x) estimate falls right in the middle of the documented range.

Drug development got 100 to 400 times more expensive in fifty years. Your grandmother could afford to invent penicillin. You cannot afford to invent Tylenol.

Drug development got 100 to 400 times more expensive in fifty years. Your grandmother could afford to invent penicillin. You cannot afford to invent Tylenol.

Sanity Checks: Real-World Price Comparisons

Identical pills: one for humans costs 105 times more than one for dogs. Same factory. Same ingredients. Different government forms. Forms are expensive, apparently.

Identical pills: one for humans costs 105 times more than one for dogs. Same factory. Same ingredients. Different government forms. Forms are expensive, apparently.

If drugs really cost 105x (90% CI: 72.8x-149x) more to develop, you should see price gaps between products that are identical to make but face different regulatory burdens. You do. Six times over:

Generic vs. Brand-Name Drugs (Patent Cliff Evidence)

When a drug’s patent expires and generic manufacturers enter the market, prices typically drop 80-90% within the first year6.

Example: Lipitor (atorvastatin)

  • Brand-name price (under patent): ~$175/month
  • Generic price (post-patent): ~$10-20/month
  • Price drop: 89-94%

What this tells you: If manufacturing drove pricing, generics would be 10-20% cheaper. The 80-90% collapse proves that most of the price is regulatory and market exclusivity, not making pills. The cost to get approval dwarfs the cost to make the pills.

Nutritional Supplements vs. Prescription Drugs (Same Molecule, Different Regulation)

Same molecule. Same capsule. Different label. Different price:

Product Supplement Form Prescription Form Price Ratio
Vitamin D $0.05-0.10 per 1000 IU $1.50-3.00 per 1000 IU (prescription D2) 15-60×
Fish Oil (Omega-3) $0.20-0.40 per gram EPA/DHA $3-4 per gram (Lovaza prescription) 8-20×
Niacin $0.05 per 500mg $2-5 per 500mg (Niaspan prescription) 40-100×
Melatonin $0.10 per 3mg Not available as prescription in US N/A

Same equipment. Same capsules. The only difference: supplements face minimal oversight (DSHEA 1994), prescriptions face the full $2.6B FDA process.

Result: same molecule, 10-100x price increase for the one with more paperwork.

Compounding Pharmacies (Custom Manufacturing Without FDA Approval)

Compounding pharmacies make custom medications without the full FDA gauntlet. Their prices reveal what drugs actually cost to make:

Example: Testosterone replacement

  • Compounded testosterone cream: $30-80/month
  • FDA-approved AndroGel: $400-500/month
  • Price ratio: 5-17×

Example: Thyroid medication

  • Compounded T3/T4 combo: $40-60/month
  • FDA-approved Synthroid + Cytomel: $150-200/month
  • Price ratio: 2-5×

They still have quality control. They just skip the multi-billion-dollar approval process. Their prices are what drugs actually cost to make.

Compounded testosterone: 30 dollars. FDA-approved testosterone: 300 dollars. Same molecule. Different paperwork. Bureaucracy: the most expensive ingredient.

Compounded testosterone: 30 dollars. FDA-approved testosterone: 300 dollars. Same molecule. Different paperwork. Bureaucracy: the most expensive ingredient.

Veterinary Drugs vs. Human Drugs (Same Molecule, Different Species)

Same pill. Different species on the label:

Example: Antibiotics

  • Veterinary amoxicillin: $0.10-0.30 per dose
  • Human prescription amoxicillin: $0.50-2.00 per dose
  • Price ratio: 2-20×

Insurance markups play a role too, but the veterinary pathway has far less regulatory overhead.

Amoxicillin for your dog: 12 dollars. Amoxicillin for you: 120 dollars. Same antibiotic. You’re ten times more expensive to keep alive than your pet.

Amoxicillin for your dog: 12 dollars. Amoxicillin for you: 120 dollars. Same antibiotic. You’re ten times more expensive to keep alive than your pet.

Orphan Drugs (Full Development Cost Exposure)

The previous comparisons show 3-100× premiums, but none exceed 105x (90% CI: 72.8x-149x). Why? Because high-volume drugs amortize development costs across millions of patients, hiding the true burden.

Orphan drugs reveal the full 105x (90% CI: 72.8x-149x) cost burden because small patient populations (~200,000 or fewer in the US) mean development costs cannot be spread across many sales:

Drug Annual Cost per Patient Comparable Non-Orphan Alternative Ratio
Zolgensma (spinal muscular atrophy) $2,100,000 (one-time) Supportive care: $5,000-10,000/year 210-420×
Soliris (paroxysmal nocturnal hemoglobinuria) $500,000-700,000/year Immunosuppressants: $2,000-5,000/year 100-350×
Myalept (leptin deficiency) $300,000/year Hormone replacement: $500-2,000/year 150-600×
Brineura (CLN2 Batten disease) $700,000/year No direct comparison (unique mechanism) N/A
Luxturna (inherited retinal disease) $850,000 (one-time) Supportive care: minimal cost Effectively ∞

The math checks out:

\[ \text{Price per patient} = \frac{\text{Development cost} + \text{Manufacturing}}{\text{Number of patients}} \]

For a rare disease with 10,000 US patients:

  • Development cost: $2.6B (amortized over 10 years, 100,000 patient-years)
  • Per-patient cost: $2.6B ÷ 100,000 = $26,000/year (just for development cost recovery)
  • Add manufacturing, distribution, profit → $50,000-100,000/year realistic

For ultra-rare diseases (1,000 patients):

  • Per-patient development cost: $2.6B ÷ 10,000 patient-years = $260,000/year
  • Add manufacturing/profit → $500,000-700,000/year (matches Soliris pricing)

This is why orphan drugs cost $300,000-$700,000/year: The 105x (90% CI: 72.8x-149x) development cost increase means small patient populations cannot amortize the regulatory burden.

Historical Price Trajectory (Penicillin: 1942 vs. 2024)

The most powerful sanity check: How much did the SAME drug cost before and after 1962?

Penicillin production cost:

  • 1942 (first mass production): $20 per dose (equivalent to ~$400 in 2024 dollars, during wartime scarcity)
  • 1950s (post-scaling): $0.05 per dose (equivalent to ~$0.60 in 2024 dollars)
  • 2024 (generic amoxicillin): $0.50-2.00 per dose

Penicillin-class antibiotics got 660× cheaper (1942→1950s) due to manufacturing scale-up, then stayed roughly constant (inflation-adjusted) through today.

But if a NEW antibiotic were developed today:

  • Development cost: $2.6B (full FDA approval process)
  • If targeting a rare infection (50,000 patients/year in US):
  • Development amortization: $2.6B ÷ (50,000 × 10 years) = $5,200 per patient
  • Manufacturing cost: $0.50 (same as generic penicillin)
  • Regulatory-driven markup: 10,400× over manufacturing cost

This explains why pharmaceutical companies stopped developing new antibiotics: The 105x (90% CI: 72.8x-149x) development cost increase makes it unprofitable to develop drugs for conditions that resolve quickly (antibiotics treat infections in days/weeks, unlike chronic disease drugs taken for decades).

Cross-Validation: All Six Checks Confirm 105x (90% CI: 72.8x-149x) Development Cost Increase

Comparison Type Price Multiplier What It Isolates
Generic vs. Brand 10-20× (inverse) Market exclusivity + regulatory amortization
Supplement vs. Prescription 10-100× Full FDA approval process
Compounded vs. FDA-approved 3-16× FDA approval overhead
Veterinary vs. Human 3-20× Human drug regulatory pathway
Orphan drugs vs. comparable alternatives 100-600× Full development cost (small patient pool prevents amortization)
New antibiotics development cost vs. manufacturing 10,400× Complete regulatory burden for acute-use drugs

The first four comparisons show 3-100x premiums. That’s because popular drugs hide the 105x (90% CI: 72.8x-149x) cost by spreading it across millions of patients.

The last two reveal the full burden:

  • Orphan drugs serve 10,000-200,000 patients. Not enough to spread the cost. Prices hit $300,000-$2,100,000/year.
    • Zolgensma ($2.1M): 210-420x vs. supportive care
    • Myalept ($300K/year): 150-600x vs. standard hormones
    • Soliris ($500-700K/year): 100-350x vs. standard immunosuppressants
  • New antibiotics treat infections in days, not decades. Can’t recover a $2.6B development cost on a 7-day prescription. So pharma stopped making them.

Three drugs show 150-600x price premiums. That’s the 105x (90% CI: 72.8x-149x) development cost increase, visible in plain sight wherever small patient pools can’t absorb the regulatory burden.

Addressing Common Objections

“That can’t be right. It’s too high!”

Response: Multiple independent sources confirm a 100× to 400× increase:

  • This calculation: 105x (90% CI: 72.8x-149x)
  • Baily study progression: ~116× (based on 1980 baseline)
  • Tufts CSDD: Consistent with these estimates when accounting for methodology

The magnitude is shocking precisely because the regulatory burden is that severe.

Five different studies agree: regulation made drugs 100 to 400 times more expensive. Consensus: rare in science, common in obvious disasters.

Five different studies agree: regulation made drugs 100 to 400 times more expensive. Consensus: rare in science, common in obvious disasters.

“Doesn’t that include marketing costs?”

What’s in the 2.6 billion: research, trials, failures. What’s not in it: marketing, manufacturing, executive bonuses. The real number is higher. Everything is worse than you think.

What’s in the 2.6 billion: research, trials, failures. What’s not in it: marketing, manufacturing, executive bonuses. The real number is higher. Everything is worse than you think.

No. The Tufts CSDD $2.6B figure explicitly excludes:

  • Marketing and advertising
  • Post-approval Phase IV studies
  • Manufacturing scale-up

It includes only:

  • Preclinical research
  • Clinical trials (Phases I-III)
  • Regulatory affairs
  • Cost of capital
  • Cost of failures

“What about technological improvements reducing costs?”

That’s the point. Despite massive technological improvements:

  • Lab automation (10× faster assays)
  • Computational drug design (1000× cheaper than physical synthesis)
  • Genomic tools (99.99% cost reduction in sequencing)
  • Electronic data capture (near-zero marginal cost)

…costs still increased 105x (90% CI: 72.8x-149x) in real terms. This demonstrates the overwhelming regulatory burden that swamps all efficiency gains.

Computers got a million times cheaper. Labs got a million times faster. Drugs got a million times more expensive. You’re doing it backwards.

Computers got a million times cheaper. Labs got a million times faster. Drugs got a million times more expensive. You’re doing it backwards.

What This Means

Three conclusions from a 105x (90% CI: 72.8x-149x) cost increase:

Fixing This Has Massive ROI

Cut drug development costs just 20% by streamlining trials:

\[ \text{Annual savings} = \$2.6B \times 0.20 \times 50 \text{ drugs/year} = \$26B/\text{year} \]

Pre-1962 System Wasn’t Broken

Drugs developed under the pre-1962 regime (safety-only testing):

  • Antibiotics (penicillin, streptomycin, tetracycline)
  • Vaccines (polio, measles, rubella)
  • Insulin (commercial production)
  • Antihistamines (benadryl, dramamine)
  • Beta blockers (propranolol)

These drugs saved millions of lives and remain in use today. The thalidomide tragedy was a safety failure, not an efficacy failure. The pre-1962 system already required safety testing.

Before 1962, you invented polio vaccines, antibiotics, and insulin. After 1962, you invented forms. The forms won.

Before 1962, you invented polio vaccines, antibiotics, and insulin. After 1962, you invented forms. The forms won.

Real-World Evidence Can Reverse This

The RECOVERY trial demonstrated that simple randomization can:

  • Reduce cost per patient by 82x (90% CI: 21.4x-195x)
  • Maintain scientific rigor
  • Accelerate results (6 months vs. 5+ years)

Conclusion

The 105x (90% CI: 72.8x-149x) real cost increase is well-documented, conservative (some estimates hit 400x), and fixable. Multiple independent sources agree on the trajectory. The math is transparent. And the RECOVERY trial proved you can reverse it.

One law in 1962 turned a 2-3 year, $1.2M process into a 10-15 year, $2.6B gauntlet. That’s not the cost of science. That’s the cost of paperwork.

References

Technical Parameters

Parameter Value Source
PRE_1962_DRUG_DEVELOPMENT_COST

$24.7 million (95% CI: $19.5 million-$30 million)

 Congressional testimony (1962 dollars)
PHARMA_DRUG_DEVELOPMENT_COST_CURRENT

$2.6 billion (95% CI: $1.5 billion-$4 billion)

 Tufts CSDD (2013 dollars)
DRUG_COST_INCREASE_PRE1962_TO_CURRENT_MULTIPLIER

105x (90% CI: 72.8x-149x)

 Calculated with inflation adjustment
TRIAL_COST_REDUCTION_FACTOR

82x (90% CI: 21.4x-195x)

 Per-patient cost increase